WuXi Biologics (Cayman) Inc
HKEX:2269
WuXi Biologics (Cayman) Inc
Revenue
WuXi Biologics (Cayman) Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Revenue
¥17B
|
CAGR 3-Years
45%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Revenue
¥40.3B
|
CAGR 3-Years
35%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Revenue
¥11.5B
|
CAGR 3-Years
31%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Revenue
¥7.4B
|
CAGR 3-Years
32%
|
CAGR 5-Years
26%
|
CAGR 10-Years
36%
|
|
Genscript Biotech Corp
HKEX:1548
|
Revenue
$839.5m
|
CAGR 3-Years
29%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Revenue
¥4.2B
|
CAGR 3-Years
57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is WuXi Biologics (Cayman) Inc's Revenue?
Revenue
17B
CNY
Based on the financial report for Dec 31, 2023, WuXi Biologics (Cayman) Inc's Revenue amounts to 17B CNY.
What is WuXi Biologics (Cayman) Inc's Revenue growth rate?
Revenue CAGR 5Y
46%
Over the last year, the Revenue growth was 12%. The average annual Revenue growth rates for WuXi Biologics (Cayman) Inc have been 45% over the past three years , 46% over the past five years .